Correlation between Interleukin 31 and clinical manifestations in children with atopic dermatitis: an observational study

Main Article Content

Emanuela Duca
Genel Sur
Ionel Armat
Gabriel Samasca
Lucia Sur


atopic dermatitis, child, IL-31, pruritus, quality of life


Background: Itching is one of the major and mandatory signs of atopic dermatitis (AD) in children. Interleukin 31 (IL-31) is strongly involved in the genesis of pruritus. In our study, 68 patients aged 0–18 years with proven AD were followed clinically. The role of IL-31 in pruritus as clinical manifestation of AD is known but its etiopathogenetic mechanism is not well known.

Methods: Serum was collected from 31 patients with moderate and severe forms of AD to determine IL-31 and its correlation with activity and severity of the disease. We also studied 30 healthy patients to compare the results of determinations. The IL-31 value was determined using the sandwich enzyme-linked-immunosorbent serologic assay (two antibodies assay). The IL-31 values were expressed as picograms per milliliter (pg/mL) and compared with activity and severity of the disease.

Results: The IL-31 value was much higher in patients with AD compared to the control group. The mean value of findings was 1600 pg/mL compared to the control group with an average of 220 pg/mL. The IL-31 values were positively correlated with the severity and activity of the disease.

Conclusions: The results of our pediatric study established the involvement of IL-31 in the pathophysiology of AD. IL-31 could be a marker of AD track.

Abstract 73 | PDF Downloads 45 HTML Downloads 2 XML Downloads 1


1. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: Elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):334–9. 10.1111/j.1468-3083.2010.03794.x. PMid: 21294778.

2. Raap U, Weißmantel S, Gehring M, Eisenberg AM, Kapp A, Fölster-Holst R. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr Allergy Immunol. 2012 May;23(3):285–8. 10.1111/j.1399-3038.2011.01241.x. PMid: 22509760.

3. Ozceker D, Bulut M, Ozbay AC, Dilek F, Koser M, Tamay Z, et al. Assessment of IL-31 levels and disease severity in children with atopic dermatitis. Allergol Immunopathol (Madr). 2018 Jul–Aug;46(4):322–325. 10.1016/j.aller.2017.10.005. PMid: 29555105.

4. Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021 Apr 28;10(9):1906. 10.3390/jcm10091906. PMid: 33924978; PMCID: PMC8124688.

5. Byeon JH, Yoon W, Ahn SH, Lee HS, Kim S, Yoo Y. Correlation of serum interleukin-31 with pruritus and blood eosinophil markers in children with atopic dermatitis. Allergy Asthma Proc. 2020 Jan 1;41(1):59–65. 10.2500/aap.2020.41.190016. PMid: 31888784.

6. Chaowattanapanit S, Choonhakarn C, Salao K, Winaikosol K, Julanon N, Wongjirattikarn R, Foocharoen C, Sompornrattanaphan M. Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms. Heliyon. 2020 Dec 1;6(12):e05621. 10.1016/j.heliyon.2020.e05621. PMid: 33305054; PMCID: PMC7711144.

7. Sur M, Boca AN, Ilies RF, Floca E, Tataru A, Sur L. Correlation between quality of life and disease severity of pediatric patients with atopic dermatitis. Exp Ther Med. 2020 Dec;20(6):189. 10.3892/etm.2020.9319. PMid: 33101479; PMCID: PMC7579765.

8. Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. New and emerging systemic treatments for atopic dermatitis. Drugs. 2020 Jul;80(11):1041–1052. 10.1007/s40265-020-01335-7. PMid: 32519223; PMCID: PMC7281689.

9. Hassan Z, Luvsannyam E, Patel D, Nukala S, Puvvada SR, Hamid P. Review of prominent cytokines as superior therapeutic targets for moderate-to-severe atopic dermatitis. Cureus. 2020 Aug 20;12(8):e9901. 10.7759/cureus.9901


11. Ramirez FD, Chen S, Langan SM, Prather AA, McCulloch CE, Kidd SA, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr. 2019 May 1;173(5):e190025. 10.1001/jamapediatrics.2019.0025. Epub 2019 May 6. PMid: 30830151; PMCID: PMC6503516.

12. Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: A systematic review and meta-analysis. JAMA Dermatol. 2019 Feb 1;155(2):178–187. 10.1001/jamadermatol.2018.4566. PMid: 30540348; PMCID: PMC6439544.

13. Kim HJ, Zeidi M, Bonciani D, Pena SM, Tiao J, Sahu S, Werth VP. Itch in dermatomyositis: The role of increased skin Interleukin-31. Br J Dermatol. 2018 Sep;179(3):669–78. 10.1111/bjd.16498 PMid: 29494763; PMCID: PMC6119520.

14. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012 Jun–Jul;91(6–7):552–66. 10.1016/j.ejcb.2011.07.006. PMid: 21982586.

15. Matyas M, Miclea D, Zaharie G. Case report: Uncommon association of ITGB4 and KRT10 gene mutation in a case of epidermolysis bullosa with pyloricatresia and aplasia cutis congenita. Front Genet. 2021 Jun;12:641977 (PubMed ahead of print). 10.3389/fgene.2021.641977.

16. Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of Interleukin-31 and Interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018 Jan;73(1):29–36. 10.1111/all.13239. Epub: 2017 Jul 20. PMid: 28670717.

17. Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, et al. The first trial of CIM331, a humanized antihuman Interleukin-31 receptor A antibody in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016 Feb;174(2):296–304. 10.1111/bjd.14207. Epub: 2015 Dec 19. PMid: 26409172.